EFPIA concerned over SPC waiver amendments

Proposed amendments to the EU’s supplementary protection certificate (SPC) manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

European Council agrees on SPC manufacturing waiver

15 February 2019 The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.

Big Pharma

EU committee approves SPC waiver

24 January 2019 The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.

Big Pharma

European pharma body criticises SPC waiver vote

6 December 2018 The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

EFPIA concerned over SPC waiver amendments

More on this story

Editor's picks

Editor's picks

More features